Not yet in the clinic, Beam’s base-edited, off-the-shelf CAR-T put on hold
On Friday, the FDA slapped a hold on Beam Therapeutics’ preclinical off-the-shelf CAR-T therapy, the biotech announced this morning.
At the end of June, the base editing biotech submitted its application to begin clinical trials for its CAR-T therapy in patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoma — aggressive white blood cell cancers that do not respond well to treatment.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 164,000+ biopharma pros reading Endpoints daily — and it's free.